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Background: A range of evidence informs decision-making on innovation in health care, including formal research
findings, local data and professional opinion. However, cultural and organisational factors often prevent the
translation of evidence for innovations into practice. In addition to the characteristics of evidence, it is known that
processes at the individual level influence its impact on decision-making. Less is known about the ways in which
processes at the professional, organisational and local system level shape evidence use and its role in decisions to
adopt innovations.
Methods: A systematic scoping review was used to review the health literature on innovations within acute and
primary care and map processes at the professional, organisational and local system levels which influence how
evidence informs decision-making on innovation. Stakeholder feedback on the themes identified was collected via
focus groups to test and develop the findings.
Results: Following database and manual searches, 31 studies reporting primary qualitative data met the inclusion
criteria: 24 were of sufficient methodological quality to be included in the thematic analysis. Evidence use in
decision-making on innovation is influenced by multi-level processes (professional, organisational, local system) and
interactions across these levels. Preferences for evidence vary by professional group and health service setting.
Organisations can shape professional behaviour by requiring particular forms of evidence to inform decision-
making. Pan-regional organisations shape innovation decision-making at lower levels. Political processes at all levels
shape the selection and use of evidence in decision-making.
Conclusions: The synthesis of results from primary qualitative studies found that evidence use in decision-making
on innovation is influenced by processes at multiple levels. Interactions between different levels shape evidence
use in decision-making (e.g. professional groups and organisations can use local systems to validate evidence and
legitimise innovations, while local systems can tailor or frame evidence to influence activity at lower levels).
Organisational leaders need to consider whether the environment in which decisions are made values diverse
evidence and stakeholder perspectives. Further qualitative research on decision-making practices that highlights
how and why different types of evidence come to count during decisions, and tracks the political aspects of
decisions about innovation, is needed.
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A range of evidence informs decision-making on
innovation in health care, including formal research
findings [1], local data [2] and professional experience
[3]. However, cultural and organisational factors often
prevent the translation of evidence for innovations
into practice [4]. The health care decision-making
and innovation studies literature has shown that the
role of evidence in decision-making on innovation is
influenced by the characteristics of evidence, e.g.
accessibility of economic evaluation [5], and processes
at the individual level. Individual level processes in-
clude preferences for evidence [6], how its interpreted
[7–9], and individuals’ credibility, personality and
experience when sharing evidence [10–12]. The role
of processes at the wider professional group (e.g. pref-
erences, professional interests and power dynamics)
and organisational level has been reviewed with re-
gard to the diffusion of innovations [13, 14], but not
in relation to their impact on how evidence informs
adoption decisions specifically. In diffusion of innova-
tions theory, decision-making is said to pass through
five stages in relation to innovations [15]. In relation
to the scope of this review, evidence is relevant at the
stages of ‘knowledge’ (information sought about the
innovation), ‘persuasion’ (information sought to reduce
uncertainty, e.g. scientific evaluations, peers’ opinions)
and ‘decision’ (evidence of trialling of new idea).
While diffusion of innovations theory highlights that
a variety of evidence influences adoption decisions, it
does so predominantly in relation to the individual’s
attitude toward an innovation to the neglect of
decision-making processes at wider contextual levels
[16]. There is no consensus about the ways in which
processes at the professional group [6, 17–19], organ-
isational [20] and local system level [21], influence
the use of evidence in decisions to adopt innovations.
The purpose of this systematic scoping review was to
understand how processes at different levels influence
the use of evidence in decision-making on health care
innovations by (1) mapping processes at the professional,
organisational and local system levels which influence
how evidence informs decision-making on innovation
and (2) collecting stakeholder feedback to validate and
develop the findings. The review focussed on primary
qualitative studies as these were appropriate for under-
standing how and why contextual processes at different
levels influence evidence use in decision-making. Quali-
tative studies can capture this context by focusing on
processes and experiences of innovation at the profes-
sional group, organisational (defined as an organisation’s
decision-making systems, culture and management prac-
tices) and local system level (the embedding of organisa-
tions in the wider environment or context) [22].Methods
Literature on evidence use in decision-making on
innovation was identified, selected and analysed using a
scoping review approach [23–25], which involved six
stages: (1) identifying the research question, (2) defining
the scope of the review, (3) study selection, (4) charting
the data, (5) reporting the results and (6) stakeholder con-
sultation. We used recommendations for undertaking
each stage systematically [24], including using two re-
searchers to independently review articles for inclusion
and defining the consultation stage’s purpose and types of
stakeholder to involve. The review was completed in ac-
cordance with Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) (Additional file 1).
A review protocol was not registered. The six stages used
in this review are described below.
Stage 1: identifying the research question
This review’s guiding research question was ‘How do
decision-making processes at the professional group, or-
ganisational, and local system level influence the use of
evidence in decisions to adopt innovations in acute and
primary health care?’ Selection of these three levels re-
flects the theorised influence of these aspects of the local
context during quality improvement processes [16, 26],
with our specific research question seeking to under-
stand their influence on evidence use in decision-making
on innovation. In addressing this question, we defined
the terms ‘evidence’, ‘innovation’ and ‘decision-making’
and how they would be captured in the review.
Evidence
The conceptual literature on evidence use highlights that
a range of evidence may impact on decisions about
innovation or improvement. The evidence-based medicine
(EBM) movement, and its extension into other areas, in-
cluding health care management, has been influential in
how evidence is conceptualised. EBM involves providing
care by integrating individual clinical expertise, evidence
from systematic research and patient choice [27]. Those
critical of EBM suggests that alternative forms of evidence,
such as patients’ views on innovations [28], and qualitative
research that provides insight into real-world contexts and
participants’ interpretations [29], should be recognised for
their role in decision-making. We adopted an inclusive
and broad working definition of evidence that included di-
verse forms of information, including academic research
findings, patient experience, professional opinion, clinical
guidance and local data.
Innovation
Innovation was defined broadly as the development and
implementation of new ideas, products, processes or or-
ganisational forms [30, 31]. Our use of the term in
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improvement. No claim was made a priori about
innovation efficacy or effectiveness, as this was assumed
to vary by innovation and may not have been assessed.
Although the term ‘innovation’ may not be used in
everyday practice to describe changes to product,
process or organisational form, these were still consid-
ered as potential forms of innovation. These include
product innovations such as robotic surgery, process
innovations including hospital-wide patient safety
programmes and new organisational forms, e.g. reconfig-
uration of acute stroke services. Innovations might relate
to service provision or commissioning and be introduced
at a system-wide level or be locally led. Studies of
innovations that were not discussed in relation to their
adoption within a service or delivery context were
excluded, e.g. early phase development of new drugs or
medical devices. Conversely, a study of pharmaceutical
innovation we included examined decision-making on
adopting new drugs for use in clinical practice [8].
Decision-making
This review included decisions about whether to adopt
new innovations or spread existing innovations up to the
point of implementation (implementation itself was con-
sidered relevant where it influenced adoption decisions).
We adopted a ‘processual’ approach to the study of
decision-making on innovation, understanding it as an
ongoing, often non-linear process that unfolds over time
[32]. Different approaches to decision-making are pos-
sible which may influence how evidence is used, ranging
from more authoritarian to participatory [15, 33]. We fo-
cussed on decision-making at the micro (professional)
and meso (organisational/local system) levels.
Stage 2: defining the scope of the review
The scoping review aimed to identify examples of evi-
dence use in decisions about innovation (or related im-
provement activity) from studies conducted in relation to
the UK National Health Service (NHS) and health systems
internationally. The review’s focus was on the influence of
interactions between evidence use and processes at the
micro (professional) and meso (organisational/system)
level on decisions to introduce or diffuse innovations.
Selection criteria were defined a priori and applied by two
researchers to the title/abstract, and then full text, of
potentially relevant papers. The review focused on
decision-making on innovations in health care services
(acute, primary) and multi-sectoral studies including
health care services. Studies that examined decisions
about innovation or other improvement activities, but did
not refer to evidence use, were excluded. Only studies
conducted in Organisation for Economic Co-operation
and Development (OECD) countries were included to aidcomparability of health care systems. Only English lan-
guage references, published since 2006, were included.
This date was chosen because it coincided with recogni-
tion among policymakers and researchers of the
challenges of mobilising evidence in health care, including
concerns about traditional models of translating research
into practice [4] and critical perspectives on EBM [34].
Studies of decision-making at the national (macro) health
system level and public health or prevention were excluded
as reviews exist in these areas [35–37]. This review focussed
on decision-making on innovation by professional groups
and organisations within local health systems, rather than
the related field of policy development, including interven-
tion design, at the national health system level [38]. An on-
line bibliographic database (EPPI-reviewer 4) was used to
store and manage references [39].
Stage 3: study selection
To identify relevant literature, social science and bio-
medical databases were searched in May 2016. A search
strategy was created for MEDLINE. Search terms in the
title or abstract were ‘innovation or improvement’, ‘deci-
sion or decision-making’, ‘evidence’ and ‘health care’.
Medical Subject Headings (MeSH) were also used, which
included ‘diffusion of innovation’, ‘translational medical
research’, ‘Evidence-based practice’, ‘knowledge bases’ and
‘decision making, organizational’. The search was
adapted for other databases: Embase, PsycINFO, Scopus,
Health Management Information Consortium (HMIC),
and EBSCO Business Source Complete (see Add-
itional file 2). Suggestions of relevant literature were
made by the wider study’s project advisory group (PAG)
[40], which included academics with relevant expertise,
practitioners with clinical insight on delivering service
change and patient representatives.
Stage 4: charting the data
A data extraction framework was used to chart information
from the included studies, including setting, type of
innovation, characteristics of evidence and quality assess-
ment (Additional file 3); study type and methods, aim and
objectives, and professional, organisational and local system
processes that influenced evidence use (Additional file 4).
Stage 5: reporting the results
The review combined aggregative/integrative and config-
urative/interpretative approaches to the synthesis of evi-
dence [41–43]. First, thematic analysis by two
researchers was used to summarise findings from exist-
ing studies (aggregative) by tabulating data extracted
from the qualitative studies. Analysis focused on the
types of evidence referred to multi-level influences on
evidence use and sector/stakeholder perspective. Second,
using meta-case analysis of the compiled literature, new
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were developed during the review (configurative). The
concept of interactions between levels (professional,
organisational, local system), and their influence on
evidence use, emerged from the meta-case analysis in
which relationships between the tabulated themes were
explored.
Stage 6: stakeholder consultation
To test and develop the results from the scoping review,
four focus groups, with 18 participants in total, were
organised with mixed stakeholder groups comprising
acute care providers (4), primary care providers (3), ser-
vice commissioners (3), patient representatives (5) and
knowledge intermediaries (3). Reporting of the focusFig. 1 PRISMA flow diagramgroups (Additional file 5) was informed by consolidated
criteria for reporting qualitative research (COREQ)
checklist [45].
Results
The database search produced 1816 results, after dupli-
cates were excluded. After screening by title and abstract
using the inclusion and exclusion criteria, 184 articles
were identified for full-text screening, 23 of which were
selected for data extraction (Fig. 1). A manual search for
relevant studies conducted after the database search,
based on searching key journals (Social Science &
Medicine, BMJ Quality & Safety, Implementation
Science, Sociology of Health & Illness) and suggestions by
PAG members, including book chapters, identified eight
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reviewed.
The quality of studies was assessed using the
Critical Appraisal Skills Programme (CASP) Qualita-
tive Checklist [46], which includes nine questions for
assessing the validity of study findings numerically
and a tenth, non-quantifiable question for judging the
overall relevance or value of the research (recognising
that the checklist represents a series of inter-related
questions for assessing study quality). After reviewing
all of the studies using the CASP checklist, we agreed
that seven studies should be considered lower quality
studies. This assessment took into account how each
study performed against the numerical questions and
making a value judgement about the quality of each
study as a whole (question ten). Those seven studies
were excluded from the thematic analysis due to low
confidence in the validity of results (studies shown in
‘greyed out’ rows in the data extraction tables).Study characteristics
A summary of the studies’ characteristics is provided in
Additional file 3. The majority of the studies was con-
ducted in the UK (14), followed by Canada (5), Australia
(5), the USA (3), Sweden (1) and Italy (2). An interview-
based study [47], of lower methodological quality, in-
cluded participants from Australia, Denmark, Ireland,
the Netherlands, Slovenia, Switzerland, Spain and
Sweden. The types of innovation examined were techno-
logical innovation (6), staff and patient involvement in
quality improvement (4), responses to clinical guidelines
or tools (7), organisational innovation including quality
improvement programmes (6) and technology assess-
ment and priority setting (8). The studies covered acute
care (16), primary care (11), commissioning (8), health
and social care (2) and mental health (1). Nearly all (28)
of the 31 studies employed qualitative interviews. In
combination with interviews, these studies used observa-
tions (9), documentary analysis (9), focus groups (4) and
surveys (5). Of the remaining three studies, two relied
on observations and one did not specify data collection
methods within a case study approach. Research
evidence was the most cited form of evidence in
decision-making on innovation (19 studies); other forms
of evidence were professional experience (15), local data
(12), national guidance (7), translational information, e.g.
education/ summaries (4), patient involvement (3) and
expert opinion (3).
There were 24 studies of sufficient quality to be included
in the thematic analysis. Thematic analysis examined how
processes at different levels (professional, organisational,
local system) influenced the use of evidence in decision-
making on innovation (Additional file 4).Professional level processes influencing evidence use
Preferences for evidence
Preferences for evidence varied by professional group
and across health care sectors. Service payers (commis-
sioners) drew on a range of evidence, including alterna-
tive evidence such as patient stories, and prioritised
local need for innovations over research evidence [14,
48]. In the acute sector, nurses tended to combine
practical (‘how to’) and scientific (‘principles’) know-
ledge, while medical professionals placed greater weight
on the latter [49]. In primary care, general practitioners
(GPs) did not necessarily privilege scientific evidence;
research-based studies were contested by GPs as results
were weighed up against their knowledge of patient need
[50]. Evidence can be given different meanings by differ-
ent stakeholders resulting in uncertainty about whether
evidence was lacking, was not of good quality, or was
limited [51].
Professional interests
Some studies highlighted that decisions to develop and
adopt innovations reflected professional interests. A
study of surgical innovation found that surgeons ‘spoke
for’ patients by introducing new techniques that would
‘make sense’ for them, even though supporting data were
lacking [52]. A study of remote care (telecare) found that
evidence was actively constructed and adapted to fit
managers’ agendas [53]. There was recognition that
evidence could be ‘gamed’ whereby evidence was found
to support decisions that had already been taken [54].
Professional interests could influence how different
stakeholders responded to evidence. A primary care
study of the failure to implement externally mandated
rules, National Service Frameworks, was linked by GPs
to concerns about the accessibility of evidence (e.g.
document length, complexity, local applicability), but the
authors suggested these were mere ‘constructions’
because the frameworks did not fit in with GPs’ professional
identities [55].
Power dynamics
Power dynamics between different professional groups in-
fluenced evidence use. A study of interventions to im-
prove prescribing practice in primary care found that
managers leading the programme privileged scientific evi-
dence, while attempting to marginalise GPs’ clinical and
experiential knowledge [50]. Similarly, managers used evi-
dence to decline clinicians’ ‘unreasonable’ requests for
innovation in the area of robotic surgery [56]. Conversely,
a study of committees considering technology coverage
found that clinicians, especially those with powerful per-
sonalities, were able to influence the committees [8]. Even
where decision-makers agreed on the evidence base for an
intervention, there could be disagreement based on
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dence should be used to make decisions and/or change
services [57].
The stakeholder feedback indicated that professional
processes influenced decision-making. They confirmed
that professional credibility of those presenting evidence,
as well as clinical leadership and ‘soft’ persuasion skills
and relationship-building (including ‘endless discus-
sions’), encouraged evidence to be taken seriously and
acted upon. There was recognition that preferences for
evidence varied by stakeholder and therefore the same
evidence often need to be framed differently to influence
different stakeholders, particularly the needs of commis-
sioners or funders of potential innovations, ‘as everybody
has different buttons’. The ongoing process of building
relationships during decision-making was more apparent
in the stories of innovation shared in the focus groups
than in the literature review (due perhaps to a lack of
processual studies in extant literature) [6].
Organisational level processes influencing evidence use
Organisational roles
Organisations contributed to assessing non-clinical as-
pects of innovation. Along with evidence of clinical need
or effectiveness, budgetary and financial issues were im-
portant in decision-making [17, 49]. Organisations en-
abled stakeholder involvement in decision-making,
including staff [11], which aided subsequent implementa-
tion [10]. Stakeholder involvement in quality improve-
ment projects, particularly patients and the public, was
supported by effective communication channels and a
‘non-hierarchical’ environment for decision-making [12].
Centralised approaches to decision-making, coupled with
a lack of communication, inhibited evidence use by plan-
ners within regional health authorities in Canada [54].
Organisations limited innovations proposed by clinicians
and other stakeholders where evidence was lacking: fund-
ing for surgical innovation was cut by a hospital due to a
lack of evidence on cost, safety and effectiveness, despite
local surgeons’ perceptions that it improved patient out-
comes and safety [52].
Organisational facilitators
A number of organisational facilitators to evidence use
in decisions about innovation were identified. In a study
of technology adoption within hospitals, access to and
use of research evidence in decision-making was enabled
by organisational processes, including infrastructure re-
development projects and an emphasis on collaboration
[6]. In a study of priority setting within a provincial
health services authority, evidence use was enabled by
strong leadership, a culture of openness and learning,
and commitment to being ‘data-driven’ [9]. The import-
ance of research culture was borne out by a study of amulti-systemic therapy, where entrepreneurial leaders of
adopter sites suggested that they could make decisions
to adopt innovations more readily than non-adopters be-
cause they were more aware of the evidence base [58].
Innovation was supported by creating leadership for
change, which included marketing evidence of benefit
and building a supportive community of practice [59].
Another study highlighted the importance of involving
both managers and clinicians in decision-making [60].
The chairs of decision-making committees moderated
the use of evidence type. A study of networks respon-
sible for enhancing multidisciplinary cancer care found
that some chairs steered the conversation more to scien-
tific and technical themes at the expense of narrative
perspectives [61].
Organisational barriers
Underlying organisational issues could act as barriers to
introducing innovations [55]. A lack of time, resources
and pressures inhibited evidence use [54]. A lack of au-
thority to make changes to processes also influenced
decision-making [9]. In some contexts, organisations
were not receptive to change. A study of telehealth ser-
vices found that its spread was limited in two out of five
cases by a lack of alignment between the adopting orga-
nisations’ values and managers’ agendas [53]. One study
suggested that those proposing innovations should en-
sure these were aligned with other activities already fa-
miliar to decision-making stakeholders [57]. Another
study found that involvement processes for enabling pa-
tient organisations to participate in funding decisions
were inadequate for including patients’ experiences [62].
Organisational politics
Organisational politics influenced the type of evidence
accessed and how it was interpreted. The use of economic
evaluation by committees making technology coverage de-
cisions was limited by unclear relationships with resource
allocators, an explicitly political decision-making process,
and poorly specified decision-making criteria [8]. A study
of commissioners’ information use [48] found that
organisational processes changed the original information
gathered during decision-making (evidence was re-framed
over time to suit competing agendas).
The stakeholder feedback confirmed that an innovation
was more likely to be adopted when it was aligned with
organisational needs, e.g. when it is a priority (including
meeting external targets or initiatives) and it addressed a
clear, practical problem. The focus groups elaborated on
the influence of the decision-making approach taken in
relation to innovations of different scales. There was rec-
ognition that large-scale change was difficult because a
wide range of stakeholders were often involved and that
evidence often showed both pros and cons. The
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tional decision-making; ‘autocratic’ as opposed to ‘demo-
cratic’ organisations were better placed to introduce
change, but once a decision had been made, there was the
challenge of getting a change accepted and having a cul-
ture that valued evidence was deemed important for this.
Local system level processes influencing evidence use
External pressures
External pressures, including system restructuring
[57], meeting policy targets [6] and budgetary con-
straint [7, 17, 59], influenced how evidence was used
in decisions about innovation. The political context
influenced decision-making [9], e.g. decisions needed
to stand up to external scrutiny [48]. Such pressures
could lead to an emphasis on ‘what works’ in making
adoption decisions over use of rigorous evidence [6].
One study reported staff being overwhelmed when
using evidence to make decisions about changing ser-
vices due to competing priorities and variable man-
agerial support during major external change [57]. A
context of austerity could encourage evidence to be
viewed differently. To receive funding, home
telehealth services needed to demonstrate savings or
efficiencies as well as evidence of benefit [59]. Due to
the need to consider rationing of the health care sys-
tem, another study argued that decision-makers
viewed economic evaluation narrowly–based on
budgetary impact and costs rather than cost effective-
ness [7]. Another study found that financial and re-
source issues facing commissioners made them more
conservative when changing services in response to
new national guidelines [60].
Pan-regional organisations
Pan-regional organisations influenced how evidence was
used in decisions about innovation. On the one hand,
such organisations had a downward influence on
evidence use in local decision-making. A study of a col-
lective primary care organisation showed how it influ-
enced GPs’ prescribing practice by emphasising evidence
that appealed to this professional group (i.e. improving
quality through prescribing targets), while deemphasiz-
ing the contribution of the interventions to cost contain-
ment which appealed less to GPs [50]. A national
improvement programme was the source of evidence for
improving ward productivity, which had a national
organisational profile and established links with pro-
viders, aiding adoption [63]. However, a regional health
technology advisory group in Sweden had less influence
on decision-making because it was not embedded suffi-
ciently in local decision-making [51]. On the other hand,
an upward relationship from the organisational to local
system level existed whereby pan-regional organisationshelped legitimise local innovations or encourage dis-
investment. Hospitals’ participation in a national
improvement campaign afforded external validation of
decision-makers’ opinions at a local level, aiding
programme commitment [56]. One Canadian study
found that a regional body was used by a hospital to
justify withdrawing funding for an innovation, based on
a perceived lack of evidence [52].
Widening stakeholder involvement
Participation in external systems or networks enabled a
wider range of potential stakeholders to inform decision-
making on innovation. However, taking into account a
range of external stakeholders’ views could hinder imple-
menting innovations based on formal evidence alone;
the politics of decision-making could be more important
than evidence, including the assessment of likely public
perceptions of decisions taken [53]. Decision-making
could be enhanced through the use of deliberative in-
volvement processes enabling multiple stakeholders to
participate [62].
The stakeholder feedback indicated that organisations
at the local system level played an important role in en-
abling innovation. The backing of research organisations
and other knowledge intermediaries, e.g. Academic
Health Science Networks and CLAHRCs, provided a fa-
cilitating role–one participant referred to them as ‘am-
bassadors’ for innovation–that could help to bring
together relevant stakeholders. The role of intermediar-
ies in mobilising evidence for innovations by brokering
social relationships came through more clearly in the
focus groups than in the literature review, possibly be-
cause studies of knowledge mobilisation tend to consider
implementation processes (which were excluded from
the review) rather than adoption decisions [21]. The
focus groups confirmed the importance of the political
context, especially perceived pressure to reduce or con-
trol costs, and the need for evidence for innovations to
align with those setting the political direction.
Discussion
Summary
This is the first systematic scoping review to examine
how processes at multiple levels (professional,
organisational, local system) influence evidence use in
decision-making on innovation. At the professional
level, preferences vary by professional group and
health service setting. Commissioners favoured
evidence derived from contact with colleagues or pro-
fessional ‘networking’, combined with service user in-
volvement and assessment of local needs rather than
research evidence. Doctors in acute settings preferred
research evidence, while those working in primary
care emphasised clinical and experiential knowledge
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dence were partly due to barriers to using some
forms of research, e.g. cost analyses, or a perceived
lack of formal evidence for making the decision at
hand. Professional interests, and dynamics of power
between professional groups, shaped the construction,
interpretation and application of evidence during
decision-making on innovation. Organisational roles in-
cluded influencing the culture of evidence use (e.g. en-
couraging decisions to be data-driven), assessing non-
clinical aspects of evidence (e.g. financial impact of
innovation) and enabling stakeholder involvement. At the
local system level, the embedding of pan-regional organi-
sations shaped innovation decision-making at lower levels,
while external pressures could encourage particular types
of evidence (e.g. cost analyses) or inhibited its use. The
politics of decision-making, e.g. linked to the financial
context in which innovations were being considered, was
an important influence on evidence use at all levels. An
overview of the themes identified is provided in Table 1.
Multi-level interactions and their influence on
evidence use
Much of the existing literature on evidence use in
decision-making on innovation has focussed on pro-
cesses at a particular level or not been explicit about
the need to study processes at different levels (a not-
able exception is Prosser and Walley’s study [50] of
the ways in which a primary care organisation
attempted to influence the prescribing strategies of
local GPs). Our synthesis of the current literature in-
stead suggests the importance of the metaphor of a
‘system’ or ‘ecology’ to encompass the multi-level in-
fluences on evidence use in decisions aboutTable 1 Overview of the themes identified through the systematic
Themes
Professional level Organisational level
Preferences for evidence Organisational roles
• Varies by professional group and
across health care sectors.
• Limit innovations where evidence lac
finance and budgetary issues, and en
stakeholder involvement.
Professional interests Organisational facilitators
• Influence professional groups’
preferences for innovations and
responses to evidence.
• Being ‘data-driven’, well informed to t
strong leadership and structures for st
involvement.
Power dynamics Organisational barriers
• Choice of evidence, its
interpretation and use in adoption
decisions negotiated.
• Time, resources and pressures; author
implement change; centralised appro
decision-making.
Organisational politics
• Shapes selection and interpretation oinnovation. The importance of interactions between
levels in influencing evidence use has emerged from
our meta-case analysis of the synthesised literature. A
map of processes at each level, and influence of the
interactions between levels, is presented in Fig. 2.
Adopting a multi-level perspective develops diffusion
of innovations theory in two ways. Firstly, the
decision-making agent is often more diffuse than the
individual unit identified in current theory. Multiple
stakeholders, including different professional groups,
provider organisations and local system intermediar-
ies, can inform adoption decisions collectively, par-
ticularly in relation to major system change in health
care. Secondly, the analytical distinction found in dif-
fusion of innovations theory between evidence, on the
one hand, and decision-making agent on the other,
should be reconsidered to account for the ways in
which these phenomena are mutually defined (e.g.
evidence informs decision-making when mobilised by
health professionals, organisations or local system
intermediaries, while such agents draw on different
types of evidence to engage with and exert influence
on decision-making).
Implications for research
The review suggests implications for how evidence
use in decisions about innovation is studied by re-
searchers. Despite critiques of EBM emerging since
the mid-2000s, rationalist conceptions of evidence
based on this approach continue to inform many pri-
mary studies of evidence use in decision-making. This
is apparent in discussions by researchers of ‘hierarch-
ies’ of evidence, where research evidence is still









• Downward influence on evidence use in local decision-
making.
• Upward relationship whereby pan-regional organisations





• External networks enable wider range of potential
stakeholders to inform decision-making.
f evidence.
Fig. 2 Interactions between evidence use and processes at different contextual levels (professional, organisational, local system). At the professional
level, evidence is constructed and interpreted by members of professional groups. Professional groups can have differing preferences, self-interests
and power relationships with other groups with regard to the use of evidence in decision-making. At the organisational level, organisations establish
requirements for evidence to support decision-making and select evidence for informing decisions. Organisations have a number of roles in enabling
evidence use; organisational barriers, facilitators and politics may shape the incorporation of evidence in decision-making. At the local system level,
evidence is validated (e.g. endorsed by pan-regional bodies) and results are tailored to different local groups and organisations. Pan-regional groups
can widen stakeholder involvement in decision-making. There are interactions between levels: professional groups apply evidence at the organisational
level, while organisations enable professions to access and use evidence; organisations use local systems’ views on evidence to legitimise innovation or
service disinvestment; and local system processes place pressure on the use of evidence for innovation (e.g. signalling the need for innovation or
service disinvestment)
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hierarchy among different types of evidence may be
implicit or explicit. For example, Evans et al. [17]
were critical of the lack of use of ‘high-grade’
research evidence by local commissioners on Welsh
Health Boards (often due to political and budgetary
pressures), highlighting the potential effect on patient
care, outcomes and resource use where research evi-
dence was lacking and decision-makers relied on local
evidence. This conclusion reflects scholarship advocat-
ing EBM whereby the quality of ‘scientific’ evidence
(using recognised and reproducible methods) should
be prioritised over local, ‘colloquial’ evidence [33].
Others question the need for research to demonstrate
quality according to EBM standards [34], with plural-
istic analyses highlighted as one potential cost [64].
Rather than evaluate the ‘quality’ of evidence through
an EBM frame which tends to privilege a clinical
perspective and formal evidence of effectiveness [27], we
suggest that other forms of evidence and stakeholder
perspectives are recognised as contributing to decision-
making on innovation in their own right and on theirown terms. As the focus groups highlighted, this inclu-
sive approach would reflect the burgeoning forms of evi-
dence now available to decision-makers (e.g. non-health
care industry evidence, patient stories, feedback from
user groups, reuse of existing data, case studies,
infographics, lay summaries and evidence to support
implementation). We suggest that such evidence diver-
sity places a responsibility on decision-makers to be
explicit about the types of evidence on which decisions
are made, the stakeholder perspectives represented and
any areas of uncertainty where evidence is lacking or
inconclusive. Improvement work by researchers could
focus on developing an explicit framework–which
includes guidance on judging diverse evidence and
stakeholder mapping–to support this activity. This
would allow practitioners to consider whether sufficient
stakeholder perspectives, and evidence reflecting those,
are adequately represented in decision-making on inno-
vations that often affect multiple groups, especially
major system change [65].
While the review found that research evidence was the
most cited form of information used in decision-making,
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of evidence, including local data and professional experi-
ence. Thus, studies at both local and policy level indicate
the importance of ‘informal’ information [35]. Further
qualitative research on practices of decision-making that
highlights how and why different types of evidence come
to count during decisions, and tracks the political as-
pects of decisions about innovation, would be fruitful
(e.g. how the validity of evidence is constructed, why
some forms of evidence might be prioritised and others
marginalised and which professional, organisational and
system level interests were influential). In existing
research, the ‘decision-maker’ responsible for making
decisions about innovation is often unclear. Future
studies should be explicit about the approach to
decision-making taken, how stakeholders were involved,
e.g. distinguishing between decision-‘makers’ and
decision ‘influencers’ [37], and how decision-making
processes influenced adoption decisions.
Strengths and limitations
In contrast to systematic reviews, some argue that the
need to formally assess the methodological quality of
studies in scoping reviews is relaxed [66]. However,
we suggest this review was strengthened by the qual-
ity assessment of the included studies, as an objective
was to provide recommendations for policy and prac-
tice that were based on robust studies. A further
strength of this review was the inclusion of stake-
holder feedback on the findings, meaning that we
were able to test the practical relevance of the themes
identified against ‘real-world’ accounts of decision-
making on innovation. It is acknowledged that the
focus groups were conducted at a time of significant
concern about NHS funding. Nonetheless, the focus
groups highlighted the importance of the financial
aspects of innovations; information that showed inno-
vations would reduce costs or be cost neutral was a
priority when assessing new and existing innovations,
confirming a concern with the financial impact of in-
novations in more recent literature published since
the financial crises [7, 17, 59, 60]. The focus groups
suggested that evidence use in decisions about service
disinvestment should be disentangled from the
broader concept of ‘innovation’ or ‘improvement’. In
future research, the attributes and impact of innova-
tions should be clearly defined to avoid forms of
change due primarily to financial constraints being
associated uncritically with the positive connotations
of the term innovation.
The results of the database search indicated that some
relevant papers were missing, based on the authors’
prior awareness of the field to develop the wider study
protocol [40]. The manual search produced 8/31included studies; a suggested reason for this relatively
high number is that some terms used to describe
innovation or improvement were not included in the
database search, e.g. service development, planning, re-
design and transformation. An additional manual search
of selected management and health policy journals,
books and grey literature was undertaken which in-
cluded these terms; bibliographies of recent and highly
relevant papers were also consulted.
Conclusions
The synthesis of results from primary qualitative studies
showed that evidence use in decision-making on
innovation is influenced by processes at multiple levels.
Moreover, our reading of the synthesised literature sug-
gests that interactions (upwards and downwards) between
conceptual levels shape evidence use in decision-making
(e.g. professional groups can use local systems to legitim-
ise innovations, while local systems can frame evidence in
particular ways to influence activity at lower levels). We
conclude with recommendations for policy and practice in
terms of enhancing the use of evidence in decisions about
innovation. First, while a range of evidence may inform
decision-making, from research evidence through to local
data and professional opinion, key decision-makers should
reflect on the types of evidence that are routinely used in
decision-making and how this influences the outcome
(e.g. how might a preference for local data over research
evidence contribute to the perceived risk of introducing
innovations?). Second, the role of politics and power in
decision-making needs to be acknowledged and skilfully
managed. Evidence can potentially have an emancipatory
role in lending authority to participants beyond other
characteristics (e.g. personal credibility and positional
power). To enable this role, organisations need to value
challenging evidence and perspectives and build staff and
organisational capacity in acquiring and applying evi-
dence. Third, decision-makers need to consider the ways
in which the environment in which decisions are made
encourages diverse evidence and perspectives. For ex-
ample, organisational leaders should consider how to miti-
gate professional interests and power when developing
processes for enabling stakeholder involvement in
decision-making.
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